Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Quebec
-
Drummondville, Quebec, Canada
-
Montreal 2 sites, Quebec, Canada
-
-
-
-
-
Ashkelon, Israel
-
Beer Sheva, Israel
-
Haifa 2 Sites, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Rechovot, Israel
-
Safed, Israel
-
Tel Aviv, Israel
-
Tel Hashomer, Israel
-
-
-
-
-
Amanzimtoti, South Africa
-
Bloemfontein, South Africa
-
Buff, South Africa
-
Durban, South Africa
-
East London, South Africa
-
Johannesburg, South Africa
-
Lyttelton Manor, South Africa
-
Port Elizabeth, South Africa
-
Pretoria, South Africa
-
-
-
-
Alabama
-
Mobile, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
Tuscon, Arizona, United States
-
-
California
-
La Jolla, California, United States
-
Los Angeles, California, United States
-
Santa Rosa, California, United States
-
-
Florida
-
Miami, Florida, United States
-
Plantation, Florida, United States
-
-
Illinois
-
Springfield, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Louisiana
-
Shreveport, Louisiana, United States
-
-
Massachusetts
-
Worchester, Massachusetts, United States
-
-
Michigan
-
Petoskey, Michigan, United States
-
-
Minnesota
-
Minneapolis, Minnesota, United States
-
-
Missouri
-
Rolla, Missouri, United States
-
St. Louis, Missouri, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
New York, New York, United States
-
-
Ohio
-
Cleveland, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
South Carolina
-
Columbia, South Carolina, United States
-
-
South Dakota
-
Sioux Falls, South Dakota, United States
-
-
Tennessee
-
Chattanooga, Tennessee, United States
-
-
Virginia
-
Norfolk, Virginia, United States
-
Salem, Virginia, United States
-
-
West Virginia
-
Huntington, West Virginia, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Serum sodium levels 115 to < 130mEq/L
- Euvolemic or Hypervolemic hyponatremia
Exclusion Criteria:
- Clinical evidence of volume depletion or dehydration
- Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency
- Uncontrolled brady-or tachyarrhythmias requiring pacemaker placement or treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The primary efficacy outcome will be change from baseline in serum sodium over the duration of treatment. The primary safety outcome will be safety parameters (e.g., adverse events, vital signs, EGG, laboratory measurements).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Art Wheeler, MD, Cumberland Pharmaceuticals, Inc.
Publications and helpful links
General Publications
- Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008 Jul;69(1):159-68. doi: 10.1111/j.1365-2265.2007.03149.x. Epub 2008 Jul 1.
- Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447-57. doi: 10.1159/000106456. Epub 2007 Jul 26.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 087-CL-027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.